Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel (ABE-DESCART)

Bristol-Myers Squibb (BMS)

Status: Active, not recruiting

Conditions: Multiple Myeloma

Treatments: Other: Not treated; Drug: Idecabtagene vicleucel

Study type: Observational

Funder types: Industry

Identifiers

NCT06154902

CA089-1041

Details and patient eligibility

About

The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.

Enrollment: 350 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with RRMM registered in the DESCAR-T registry and eligible for treatment or treated with idecabtagene vicleucel

Exclusion criteria

• Not registered with the social security in France

Trial design

350 participants in 2 patient groups

Treated with idecabtagene vicleucel

Treatment:

Drug: Idecabtagene vicleucel

Eligible for idecabtagene vicleucel

Description:

Eligible for idecabtagene vicleucel treatment but not treated

Treatment:

Other: Not treated